REGENXBIO Inc. RGNX R2K
Healthcare · Biotechnology · United States
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
READ MORE ›$7.01
-20.79% 1Y
Market & Price
Market Cap
$362.40M
Current Price
$7.01
High / Low (52W)
$15.98 / $5.65
Beta
1.12
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$0.41
Price to Book
17.18
P/S
4.13
EV/EBITDA
-1.91
Dividend Yield
-
Profitability & Returns
ROCE
-44.45%
ROE
-
ROA
-38.53%
Profit Margin
0.00%
Op Margin
-
EPS (Latest Qtr)
$-1.72
EPS (TTM)
$-5.60
Balance Sheet & Liquidity
Debt/Equity
11.78
Quick Ratio
2.44
Current Ratio
2.62
Debt
$248.40M
Total Assets
$453.03M
Current Assets
$281.28M
Working Capital
$163.19M
Ownership
Promoter Holding
7.78%
Chg in Prom Hold
-
FII / Inst Holding
84.76%
Chg in FII Hold
-0.02%
Financial Snapshot
Enterprise Value
$460.31M
Total Revenue (TTM)
$87.82M
EBITDA
$-241.17M
Free Cash Flow
$-138.98M
Operating Cash Flow
$-233.78M
Shares Outstanding
51.70M
Gross Margin
-
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
14.78%
Profit 5Y
10.28%
Revenue (YoY)
-92.80%
Earnings (YoY)
-
PROS
- Compounding revenue at 14.8% over 5 years.
- Profit CAGR of 10.3% over 5 years.
CONS
- Trading 56.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RGNX REGENXBIO Inc. R2K | 7.01 | - | $362.40M | - | -44.45% | - | 14.78% | 10.28% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 455.00K | 6.56M | 1.34M | 2.04M | 132.39M | 40.03M | 5.31M | 40.78M | 884.00K | 7.88M | 14.70M | 11.77M | 17.64M | 16.57M | 98.91M | 21.45M | 18.88M | 22.04M | 30.77M | 22.22M | 32.65M | 26.51M | 19.14M | 19.98M | 28.91M | 15.62M | 22.30M | 24.20M | - | 89.01M | 21.36M | 29.73M | 30.34M | 6.39M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.44M | 5.21M | 5.72M | 5.93M | 11.07M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 85.58M | 16.15M | 24.01M | 24.41M | -4.68M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 73.45M | 79.43M | 76.42M | 82.05M | 78.68M |
| Operating Income | -7.35M | - | -11.25M | -14.95M | -18.67M | - | -22.92M | -15.06M | -21.31M | - | 102.03M | 6.35M | -22.73M | - | -35.91M | -36.87M | -35.90M | - | -37.70M | -41.83M | 13.95M | - | -44.04M | -52.23M | -57.35M | -71.53M | -62.53M | -71.05M | -66.16M | -73.11M | -64.96M | -63.86M | -56.04M | -62.08M | - | 12.13M | -63.28M | -52.41M | -57.64M | -83.36M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.61M | -55.97M | -44.89M | -51.00M | -77.49M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.57M | 10.99M | 13.17M | 12.28M | 8.71M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.08M | -70.87M | -61.94M | -67.15M | -90.05M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -7.33M | -5.18M | -10.77M | -14.44M | -18.15M | -19.61M | -21.99M | -14.47M | -20.71M | -16.00M | 104.24M | 10.59M | -19.20M | 4.31M | -32.23M | -1.46M | -34.58M | -26.46M | -40.04M | -33.76M | 8.79M | -46.24M | -50.14M | -57.64M | -58.41M | -76.72M | -68.18M | -75.48M | -66.68M | -72.06M | -61.87M | -63.33M | -52.99M | -59.60M | - | 6.08M | -70.87M | -61.94M | -67.15M | -90.05M |
| Diluted EPS | - | - | - | - | - | - | -0.82 | -0.47 | -0.67 | -0.51 | 3.04 | 0.30 | -0.56 | 0.11 | -0.89 | -0.04 | -0.94 | -0.72 | -1.08 | -0.91 | 0.23 | -1.24 | - | -1.36 | -1.37 | -1.79 | -1.58 | -1.75 | -1.53 | -1.66 | -1.41 | -1.38 | -1.05 | -1.17 | - | 0.12 | -1.38 | -1.20 | -1.30 | -1.72 |
| R&D Expense | 5.66M | 4.81M | 6.18M | 10.68M | 12.56M | 16.06M | 16.62M | 13.92M | 12.52M | 14.17M | 19.55M | 21.49M | 18.51M | 24.33M | 25.20M | 29.48M | 35.69M | 33.81M | 37.03M | 38.11M | 43.97M | 47.18M | 39.72M | 45.88M | 47.85M | 55.63M | 61.01M | 63.31M | 58.52M | 59.89M | 58.18M | 54.84M | 48.87M | 54.43M | - | 53.09M | 59.50M | 56.10M | - | 57.34M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 4.59M | 10.39M | 218.50M | 35.23M | 154.57M | - | 112.72M | 90.24M | 83.33M | 170.44M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | 54.55M | 37.21M | 33.57M | 20.30M |
| Gross Profit | - | - | - | - | - | - | - | - | - | 58.18M | 53.03M | 49.76M | 150.14M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 321.06M | 321.16M | 281.01M | 311.34M |
| Operating Income | -4.78M | -3.68M | -23.14M | -65.34M | -75.89M | 88.10M | -149.00M | -119.23M | - | -262.88M | -268.13M | -231.25M | -161.20M |
| EBITDA | - | - | - | - | - | - | - | - | - | -244.24M | -239.46M | -198.23M | -133.25M |
| Interest Expense | - | - | - | - | - | - | - | - | - | 23.25M | 6.86M | 12.66M | 45.01M |
| Pretax Income | - | - | - | - | - | - | - | - | - | -280.40M | -263.65M | -227.10M | -193.88M |
| Tax Provision | - | - | - | - | - | - | - | - | 13.41M | -84.00K | -152.00K | 0 | - |
| Net Income | -5.39M | -4.00M | -22.81M | -62.97M | -73.17M | 99.94M | -94.73M | -111.25M | - | -280.32M | -263.49M | -227.10M | -193.88M |
| Diluted EPS | - | - | - | -2.38 | -2.45 | 2.73 | -2.58 | -2.98 | 2.91 | -6.50 | -6.02 | -4.59 | - |
| R&D Expense | 5.05M | 4.96M | 17.28M | 45.48M | 57.22M | 83.87M | 124.19M | 166.29M | 181.44M | 242.45M | 232.27M | 208.52M | 228.30M |
Compounded Sales Growth
| 5 Years: | 14.78% |
| 1 Year: | -92.80% |
Compounded Profit Growth
| 5 Years: | 10.28% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -20.79% |
| 6 Months: | -47.88% |
| 3 Months: | -22.46% |
| 1 Month: | -16.55% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 3.49M | 221.38M | 172.73M | 198.68M | 543.81M | 497.91M | 708.16M | - | 833.27M | 573.97M | 465.99M | 453.03M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | 415.98M | 334.97M | 278.00M | 281.28M |
| Cash & Equivalents | 2.17M | 1.12M | 1.12M | 54.12M | 24.84M | 46.66M | 75.56M | 69.51M | 338.43M | - | 96.95M | 34.52M | 57.53M | 34.47M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | 280.00K | 4.85M | 65.00K | 557.00K |
| Total Liabilities | - | - | 9.19M | 4.57M | 10.99M | 15.65M | 34.97M | 47.71M | 330.41M | - | 317.07M | 262.23M | 206.34M | 350.30M |
| Current Liabilities | - | - | 9.19M | 4.34M | 9.67M | 14.44M | 22.18M | 33.68M | 81.45M | - | 130.43M | 130.27M | 103.19M | 118.09M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | 94.80M | 89.29M | 82.03M | 73.50M |
| Total Equity | -8.11M | -13.92M | -18.29M | 216.81M | 161.74M | 183.03M | 508.85M | 450.20M | 377.75M | - | 516.20M | 311.74M | 259.65M | 102.73M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | 43.30M | 44.05M | 49.55M | 50.89M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | -48.56M | -57.99M | 104.65M | -107.70M | -54.06M | - | -207.49M | -218.41M | -173.12M | -123.96M |
| Investing Cash Flow | - | 19.39M | -4.79M | -279.36M | 93.56M | 122.76M | - | -11.93M | 190.94M | 103.45M | -15.87M |
| Financing Cash Flow | - | 119.00K | 84.60M | 204.44M | 8.38M | 200.21M | - | -28.84M | -34.97M | 92.68M | 116.77M |
| Capital Expenditure | -522.00K | -8.15M | -7.16M | -13.28M | -11.72M | -26.87M | - | -30.72M | -9.96M | -2.44M | -2.41M |
| Free Cash Flow | - | -56.71M | -65.15M | 91.37M | -119.42M | -80.93M | - | -238.21M | -228.37M | -175.56M | -126.38M |
| Net Change in Cash | - | - | - | - | - | - | - | -248.26M | -62.43M | 23.00M | -23.06M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | 51.6% | 58.8% | 59.7% | 88.1% |
| Operating Margin % | - | - | - | -1,423.8% | -730.2% | 40.3% | -422.9% | -77.1% | - | -233.2% | -297.1% | -277.5% | -94.6% |
| Net Margin % | - | - | - | -1,372.1% | -704.0% | 45.7% | -268.9% | -72.0% | - | -248.7% | -292.0% | -272.5% | -113.8% |
| ROE % | 38.7% | 21.9% | -10.5% | -38.9% | -40.0% | 19.6% | -21.0% | -29.5% | - | -54.3% | -84.5% | -87.5% | -188.7% |
| ROCE % | - | 64.6% | -10.7% | -40.1% | -41.2% | 16.9% | -32.1% | -19.0% | - | -37.4% | -60.4% | -63.7% | -48.1% |
Shareholding Pattern
Insiders
7.78%
Institutions
84.76%
Public Float
91.91%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 11.19% | 5.78M | $40.54M |
| 2 | Redmile Group, LLC | 8.45% | 4.37M | $30.63M |
| 3 | JPMORGAN CHASE & CO | 6.74% | 3.48M | $24.42M |
| 4 | State Street Corporation | 5.28% | 2.73M | $19.15M |
| 5 | Morgan Stanley | 4.00% | 2.07M | $14.48M |
| 6 | Vanguard Capital Management LLC | 3.88% | 2.01M | $14.07M |
| 7 | Goldman Sachs Group Inc | 3.56% | 1.84M | $12.89M |
| 8 | Integral Health Asset Management, LLC | 2.90% | 1.50M | $10.52M |
| 9 | Qube Research & Technologies Ltd | 2.53% | 1.31M | $9.19M |
| 10 | Geode Capital Management, LLC | 2.20% | 1.14M | $7.97M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RGNX
No recent headlines available.